10th Congress of the European Academy of Neurology, Helsinki, Finland, June 29-July 2, 2024
The following summarizes some of the data presented at EAN 2024.
Neurology
REPORT FROM EAN 2024 – WEDNESDAY, JULY 3, 2024
July 3, 202410th Congress of the European Academy of Neurology, Helsinki, Finland, June 29-July 2, 2024
The following summarizes some of the data presented at EAN 2024.
REPORT FROM EAN 2024 – TUESDAY, JULY 2, 2024
July 2, 202410th Congress of the European Academy of Neurology, Helsinki, Finland, June 29-July 2, 2024
The following summarizes some of the data presented at EAN 2024.
Use of neurofilament-light chain (NfL) in the management of patients with multiple sclerosis
June 27, 2024Summarizes recent guidance on the use of NfL in clinical practice. Includes management algorithms published by Freedman et al. eBioMedicine 2024;101:104970.
8 slides
Inertia and uncertainty: is MS treatment truly optimized?
June 25, 2024SPECIAL REPORT
Numerous head-to-head trials in multiple sclerosis have demonstrated the benefits of treatment with a higher-efficacy versus modest-efficacy disease-modifying therapy (DMT). Examples include the TRANSFORMS (fingolimod vs. interferon-b), CARE-MS (alemtuzumab vs. interferon-b), OPERA I/II (ocrelizumab vs. interferon-b), and ASCLEPIOS I/II (ofatumumab vs. teriflunomide) trials in relapsing MS. Read More